查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1931218

伽瑪束立體定位放射治療系統市場（按組件、應用和最終用戶分類），全球預測（2026-2032）

Gamma Beam Stereotactic Radiotherapy System Market by Component, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年，伽瑪束立體定位放射治療系統市場價值為 1.5902 億美元，預計到 2026 年將成長至 1.7425 億美元，預計到 2032 年將達到 2.6667 億美元，複合年成長率為 7.66%。

關鍵市場統計數據
基準年 2025 1.5902億美元
預計年份：2026年 1.7425億美元
預測年份 2032 2.6667億美元
複合年成長率 (%) 7.66%

權威概述聚焦於顱內放射治療平台，重點在於針對複雜神經系統疾病的精準治療、影像整合和臨床工作流程協調。

伽瑪束立體定位放射治療系統是一類獨特的精準治療平台，旨在將聚焦輻射精準輸送至顱內標靶區，同時保護周圍正常組織。這些系統結合了精密的束流準直、亞毫米級的患者定位精度和先進的影像引導技術，可實現單次或低分割治療方法，尤其適用於複雜的顱內病變。臨床醫生越來越重視整合了強大的影像模式、自適應治療計劃和簡化的工作流程的系統，以支援快速且可重複的治療實施。

整合型成像、先進准直、人工智慧驅動的治療計劃以及一體化服務模式正在重新定義放射外科中心的治療精度和臨床工作流程。

立體定位放射外科的格局正在迅速變化，這主要得益於技術融合、不斷累積的臨床證據以及不斷發展的治療模式。影像融合技術的進步，特別是CT和MRI資料集在計畫和術中引導中的整合，提高了靶區勾畫的精確度，並實現了對關鍵結構周圍更嚴格的安全邊界。同時，準直器技術的改進，包括更靈活的扇形設計，在維持或提高劑量適形性的同時，增強了治療的柔軟性，並提高了單次放射放射線手術轉移性疾病和某些功能性疾病的可行性。

評估 2025 年關稅趨勢如何改變醫療設備採購、服務合約和資本財籌資策略，加速供應鏈韌性措施。

美國2025年生效的關稅政策為資本密集醫療設備供應商及其採購者—醫療系統—帶來了額外的成本和供應鏈的不確定性。最直接的影響體現在零件採購決策上，尤其是那些依賴特殊製造製程和進口零件的子系統，例如準直器機構和成像硬體。因此，採購團隊和供應商開始重新評估供應商契約，加快雙源採購策略的實施，並權衡短期價格調整和長期供應商整合之間的利弊，以確保關鍵零件的供應和設備的運作。

將臨床適應症、臨床環境、硬體和軟體權衡以及端到端服務需求與臨床結果和採購優先事項聯繫起來的細分市場分析

細緻的細分觀點能夠清楚展現臨床價值與商業性機會在應用、終端使用者、組件和服務層面的交會點。應用層級的差異化至關重要，因為動靜脈畸形需要高精度的放射外科局部照射，腦腫瘤需要與手術和全身治療協調的多模態治療計劃，腦轉移瘤需要快速週轉和單次或低分割照射計劃，而三叉神經痛則需要功能性標靶治療並最大限度地減少副作用。這些臨床差異會影響設備配置的選擇和臨床工作流程的設計。

臨床應用、報銷促進因素和基礎設施投資的區域差異，正在塑造美洲、歐洲、中東和非洲以及亞太地區的差異化應用策略。

區域趨勢影響立體定位放射手術的技術採納、報銷途徑以及臨床網路結構。在美洲，成熟的研究型醫院體系、認可立體定位放射放射線手術療效的支付方報銷模式以及強勁的資本市場，都為早期採用整合影像和軟體主導平台提供了支援。主要都會地區的卓越醫療中心作為轉診和培訓中心，制定了其他醫療機構效仿的臨床通訊協定。同時，在適當的臨床管治下，門診機構也擴大參與特定手術的實施。

競爭優勢源自於整合的臨床證據、模組化的軟硬體平台、社區服務網路以及能夠滿足醫療服務提供者不斷變化的需求的靈活商業模式。

在該領域，競爭優勢將越來越取決於企業如何平衡產品差異化、臨床證據產生和服務品質。將模組化硬體與先進治療計畫平台結合的主要企業，能夠縮短整個治療流程的時間，並拓展臨床適應症範圍，從而提供極具吸引力的價值提案。與學術機構和研究型醫院進行策略合作，可以加速臨床檢驗，並為指南採納鋪平道路；而與影像設備供應商建立夥伴關係，則有助於更緊密地整合治療計劃和術中影像技術。

為技術提供者和醫療系統提供切實可行的策略和營運措施，以加速安全應用、最佳化生命週期經濟效益並維持臨床療效

產業領導者必須採取切實可行的措施，確保營運的永續性，同時贏得臨床信任。投資於支援CT和MRI規劃工作流程的整合成像相容性，並提供模組化準直器選項，將擴大臨床應用範圍，並減少機構層面的客製化需求。同樣重要的是，優先改進軟體，以實現常規規劃任務的自動化，加快品質保證流程，並向多學科團隊呈現具有臨床意義的規劃權衡方案。此外，與學術和研究機構正式合作，共同製定通訊協定並發表研究成果，將有助於支付者和指南制定決策。

採用混合調查方法，結合臨床醫師訪談、技術規範審核、法規審查和供應鏈分析，以獲得可靠且可操作的見解。

本分析整合了原始定性資料和二手技術審查，以確保實證的嚴謹性和臨床相關性。原始研究包括對放射腫瘤科醫生、神經外科醫生、醫學物理學家、醫院採購經理和服務工程師進行結構化訪談，以了解臨床、技術和財務決策標準。二手研究回顧了同行評審的臨床文獻、醫療設備監管文件、診斷影像和劑量學技術報告以及已發布的醫院採購框架，以檢驗技術聲明和服務模式。

整合臨床、技術和營運方面的優先事項，突顯決定持續應用和持續臨床影響的關鍵因素

整體評估發現，技術能力、服務成熟度和營運韌性已趨於整合，這預示著將決定長期成功的關鍵轉折點。在臨床方面，該系統能夠提供精確的劑量測定、整合成像和簡化的治療計劃，滿足神經外科和放射腫瘤科團隊治療動靜脈畸形、原發性和轉移性腦瘤以及三叉神經痛等功能性疾病的核心需求。在商業方面，該系統能夠提供永續的服務協議、模組化硬體選項以及可加速吞吐量的軟體平台，從而為從學術機構到門診手術中心等各類終端用戶創造極具吸引力的價值提案。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 伽瑪束立體定位放射治療系統市場（按組件分類）

  • 硬體
    • 準直器系統
      • 固定準直器
      • 扇形準直器
    • 影像系統
      • 基於CT的影像
      • 基於磁振造影的成像
    • 病人定位系統
  • 軟體
    • 輻射控制系統
    • 治療計劃平台
  • 服務
    • 安裝和試運行
    • 預防性維護
    • 培訓和支持

9. 伽瑪束立體定位放射治療系統市場（依應用分類）

  • 動靜脈畸形
  • 腦腫瘤
  • 轉移性腦病變
  • 三叉神經痛

10. 伽瑪束立體定位放射治療系統市場（以最終用戶分類）

  • 學術研究機構
  • 門診手術中心
  • 癌症研究所
  • 醫院

11. 各地區伽瑪束立體定位放射治療系統市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第12章 伽瑪束立體定位放射治療系統市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

13. 各國伽瑪束立體定位放射治療系統市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

14. 美國伽瑪束立體定位放射治療系統市場

第15章 中國伽瑪束立體定位放射治療系統市場

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Accuray Incorporated
  • Brainlab AG
  • C-Rad AB
  • Canon Medical Systems Corporation
  • Elekta AB
  • GE Healthcare
  • Hitachi, Ltd.
  • IBA Worldwide
  • LinaTech LLC
  • Mevion Medical Systems, Inc.
  • Mitsubishi Electric Corporation
  • Neusoft Medical Systems Co., Ltd.
  • Philips Healthcare
  • ProTom International, Inc.
  • RaySearch Laboratories AB
  • Shenzhen Anke High-tech Co., Ltd.
  • Shinva Medical Instrument Co., Ltd.
  • Sumitomo Heavy Industries, Ltd.
  • TopGrade HealthCare Inc.
  • Toshiba Corporation
  • United Imaging Healthcare Co., Ltd.
  • Varian Medical Systems, Inc.
  • ViewRay, Inc.
  • Wandong Medical Equipment Co., Ltd.
Product Code: MRR-7B550E008DC6

The Gamma Beam Stereotactic Radiotherapy System Market was valued at USD 159.02 million in 2025 and is projected to grow to USD 174.25 million in 2026, with a CAGR of 7.66%, reaching USD 266.67 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 159.02 million
Estimated Year [2026] USD 174.25 million
Forecast Year [2032] USD 266.67 million
CAGR (%) 7.66%

An authoritative overview of focused intracranial radiosurgery platforms emphasizing precision delivery, imaging integration and clinical workflow alignment for complex neurological indications

Gamma beam stereotactic radiotherapy systems represent a distinct class of high-precision therapeutic platforms designed to deliver focused radiation to intracranial targets while sparing surrounding healthy tissue. These systems combine refined beam collimation, submillimeter patient positioning accuracy, and advanced imaging guidance to enable single-session and hypofractionated treatment regimens that are particularly well suited for complex intracranial pathologies. Clinicians increasingly prioritize systems that integrate robust imaging modalities, adaptive treatment planning, and streamlined workflows to support fast, reproducible care delivery.

Clinical indications for this technology span arteriovenous malformation, primary and secondary brain tumors, metastatic brain disease, and functional targets such as trigeminal neuralgia. End users for these systems include academic and research institutes driving clinical innovation, hospitals providing high-volume neurosurgical and radiation oncology services, ambulatory surgical centers adapting to outpatient procedural models, and dedicated cancer research institutes pursuing translational studies. As hospitals and specialty centers evaluate these platforms, decision criteria center on dosimetric accuracy, imaging compatibility, service and training support, and the ability to integrate into multi-disciplinary care pathways that include neurosurgery, neuro-oncology, and radiation physics.

How convergent imaging, advanced collimation, AI-enabled treatment planning and integrated service models are redefining therapeutic precision and clinical workflows across radiosurgery centers

The landscape for stereotactic radiotherapy is shifting rapidly under the influence of technological convergence, clinical evidence expansion, and evolving care models. Advances in imaging integration-particularly the blending of CT and MRI datasets into planning and intra-procedural guidance-have raised the bar for target delineation and enabled tighter margins around critical structures. Concurrently, improvements in collimator technology, including more versatile sectorized designs, have increased treatment flexibility while preserving or enhancing dose conformity, making single-session radiosurgery for metastatic disease and select functional disorders more feasible.

Software-driven innovation likewise drives change: treatment planning platforms with faster optimization engines, automation for contouring and plan generation, and the early incorporation of machine learning to predict dosimetric trade-offs shorten time from referral to treatment. Service models are also transforming; providers expect not only installation and commissioning but ongoing preventive maintenance, rapid corrective responses, and comprehensive training programs that embed competency in multidisciplinary teams. These shifts coalesce around a central theme: systems that offer end-to-end clinical and operational integration, from imaging through delivery and post-treatment follow-up, will define competitive differentiation.

Assessing how 2025 tariff dynamics altered component sourcing, service contracts and procurement strategies for capital medical devices and drove accelerated supply-chain resilience measures

United States tariff actions in 2025 introduced a layer of cost and supply-chain uncertainty for capital-intensive medical equipment suppliers and health systems procuring them. The immediate effects were visible in component sourcing decisions, particularly for subsystems such as collimator mechanisms and imaging hardware that rely on specialized manufacturing and imported parts. As a consequence, procurement teams and vendors began reevaluating supplier contracts, accelerating dual-sourcing strategies, and examining the trade-offs between short-term price adjustments and long-term supplier consolidation to secure critical parts and sustain uptime commitments.

Beyond direct input cost pressure, tariffs influenced strategic decisions around local assembly, service footprint expansion, and inventory policies. Some manufacturers prioritized increased domestic content in high-risk components to shield pricing from further tariff volatility, while others offered extended service plans and consumable bundling to smooth lifecycle costs for end users. Health systems responded by intensifying total-cost-of-ownership analyses that place heavier emphasis on service reliability, spare-part availability, and training that reduces corrective maintenance incidence. In sum, tariff-driven dynamics pushed both suppliers and purchasers toward resilience measures that emphasize supply-chain transparency, maintenance-first commercial propositions, and modular system architectures that can better tolerate component substitution without degrading clinical performance.

Segment-level analysis linking clinical indication, care setting, hardware and software trade-offs and end-to-end service requirements to clinical outcomes and procurement priorities

A nuanced segmentation view clarifies where clinical value and commercial opportunity intersect across applications, end users, components and services. Application-level differentiation matters because arteriovenous malformations demand extreme precision and radiosurgical nidus coverage, brain tumors require multimodal planning with potential surgery or systemic therapy coordination, metastatic brain disease often benefits from rapid throughput and single- or few-fraction regimens, and trigeminal neuralgia emphasizes functional targeting and secondary effects minimization. These clinical distinctions shape both device configuration choices and clinical workflow design.

End-user segmentation further refines requirements: academic and research institutes prioritize extensibility for protocol-driven innovation and robust data capture, hospitals require streamlined interoperability with existing imaging and oncology information systems, ambulatory surgical centers emphasize compact footprints and fast turnover, and cancer research institutes focus on integration with trial infrastructure. Component segmentation underscores the technical trade-offs between hardware and software investments. Hardware choices span the collimator system with options such as fixed versus sector collimators, imaging systems ranging from CT-based to MRI-based architectures, and patient positioning systems that deliver submillimeter repeatability. Software distinctions include delivery control systems versus treatment planning platforms, with planning tools increasingly central to efficiency and plan quality. Finally, service segmentation-covering installation and commissioning, preventive maintenance, corrective maintenance, and training and support-becomes a determinant of clinical uptime and user confidence, with full lifecycle service models proving essential for sustaining complex intracranial programs.

Regional contrasts in clinical adoption, reimbursement drivers and infrastructure investments shaping differentiated deployment strategies across the Americas, EMEA and Asia-Pacific

Regional dynamics influence technology adoption, reimbursement pathways, and the structure of clinical networks that deliver stereotactic intracranial care. In the Americas, a mature ecosystem of research hospitals, insurer reimbursement models that recognize stereotactic radiosurgery efficacy, and strong capital markets support the early adoption of integrated imaging and software-led platforms. Centers of excellence in major metropolitan areas act as referral hubs and training centers, shaping clinical protocols that other institutions emulate, while ambulatory settings increasingly participate in delivering selected procedures under appropriate clinical governance.

Europe, the Middle East and Africa exhibit heterogeneous adoption patterns driven by national regulatory frameworks, public health procurement cycles, and variable access to specialized personnel. Western European centers place a premium on clinical evidence and interoperability with national health records, while certain Middle Eastern health systems pursue rapid modernization through targeted capital investment. In Africa, adoption concentrates in select tertiary centers and research collaborations, with emphasis on durable service agreements. Asia-Pacific demonstrates a dynamic mix of innovation and scale: high-income markets invest in advanced imaging integration and academic partnerships, while emerging markets focus on expanding access through tiered service offerings, training programs, and selective local manufacturing or assembly to manage cost and supply continuity.

Competitive differentiation driven by integrated clinical evidence, modular hardware-software platforms, localized service networks and flexible commercial models to match evolving provider needs

Competitive advantage in this sector increasingly depends on how companies balance product differentiation, clinical evidence generation, and service excellence. Leading suppliers that combine modular hardware with sophisticated treatment planning platforms can offer compelling value propositions by reducing total time in the treatment pathway and enabling a broader set of clinical indications. Strategic collaborations with academic centers and research hospitals accelerate clinical validation and create pathways for guideline inclusion, while partnerships with imaging vendors facilitate tighter integration between treatment planning and intra-procedural imaging.

Service architecture also differentiates firms: those offering comprehensive installation and commissioning services, predictable preventive maintenance schedules, rapid corrective response, and immersive training and support programs find greater acceptance among high-volume centers that cannot tolerate extended downtime. Additionally, supply-chain strategies, such as regional parts depots and local service technicians, reduce time to repair and support tariff mitigation efforts. Finally, companies that adopt flexible commercial models-blending capital purchase, leasing, and outcome-linked agreements-respond more effectively to institutional budget constraints and changing care delivery models.

Practical strategic and operational actions for technology providers and health systems to accelerate safe adoption, optimize lifecycle economics and sustain clinical outcomes

Industry leaders must take deliberate, actionable steps to capture clinical trust while ensuring operational sustainability. Investing in integrated imaging compatibility-supporting both CT- and MRI-based planning workflows-and offering modular collimator options can broaden clinical applicability and reduce site-level customization. Equally important is the prioritization of software improvements that automate routine planning tasks, accelerate quality assurance processes, and surface clinically meaningful plan trade-offs to multidisciplinary teams. Leaders should also formalize partnerships with academic and research institutes to co-develop protocols and publish outcomes that inform payer and guideline decisions.

Operationally, companies should expand regional service footprints, create inventory buffers for high-failure-rate components, and provide robust training programs that certify local clinical and technical staff. Pricing strategies that include flexible financing, pay-per-use pilots, and bundled service offerings can lower the barrier to adoption for ambulatory centers and hospitals with constrained capital. Finally, proactive engagement with regulators and payers to demonstrate clinical value and real-world outcomes will reduce adoption friction and create durable pathways for technology uptake.

Mixed-method research design combining clinician interviews, technical specification audits, regulatory review and supply-chain mapping to ensure robust and actionable insights

This analysis synthesizes primary qualitative inputs and secondary technical review to ensure both empirical rigor and clinical relevance. Primary research consisted of structured interviews with practicing radiation oncologists, neurosurgeons, medical physicists, hospital procurement leaders, and service engineers to capture decision criteria across clinical, technical, and financial dimensions. Secondary research included review of peer-reviewed clinical literature, device regulatory filings, imaging and dosimetry technical notes, and publicly available hospital procurement frameworks to validate technical claims and service models.

Analytical methods emphasized triangulation across sources, mapping component-level supply chains, and scenario analysis for procurement and service outcomes under varying policy and tariff environments. Quality controls included cross-validation of technical specifications with practicing physicists and independent review of clinical workflow assumptions by multidisciplinary clinicians. Limitations center on the rapidly evolving nature of software-enabled features and regional regulatory shifts; where uncertainty exists, the analysis highlights probable directional impacts rather than definitive projections.

Synthesis of clinical, technical and operational priorities highlighting the imperatives that will determine durable adoption and sustained clinical impact

The cumulative assessment points to an inflection where technology capability, service sophistication, and operational resilience converge to determine long-term success. Clinically, systems that offer precise dosimetry, integrated imaging, and streamlined treatment planning address the core needs of neurosurgical and radiation oncology teams treating arteriovenous malformation, primary and metastatic brain tumors, and functional indications such as trigeminal neuralgia. Commercially, the ability to offer durable service agreements, modular hardware options, and software platforms that accelerate throughput creates compelling value propositions for a range of end users from academic institutes to ambulatory surgical centers.

Looking ahead, predictable service delivery, supply-chain transparency, and partnerships that yield clinical evidence will be the most important differentiators. Organizations that align product development with clinician workflow needs and that embed comprehensive training and maintenance into their commercial offerings will reduce barriers to adoption and sustain clinical performance. In short, the market rewards solutions that address both the technical challenge of precise intracranial targeting and the operational demands of delivering high-volume, reliable care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Gamma Beam Stereotactic Radiotherapy System Market, by Component

  • 8.1. Hardware
    • 8.1.1. Collimator System
      • 8.1.1.1. Fixed Collimator
      • 8.1.1.2. Sector Collimator
    • 8.1.2. Imaging System
      • 8.1.2.1. CT Based Imaging
      • 8.1.2.2. MRI Based Imaging
    • 8.1.3. Patient Positioning System
  • 8.2. Software
    • 8.2.1. Delivery Control System
    • 8.2.2. Treatment Planning Platform
  • 8.3. Services
    • 8.3.1. Installation & Commissioning
    • 8.3.2. Preventive Maintenance
    • 8.3.3. Training & Support

9. Gamma Beam Stereotactic Radiotherapy System Market, by Application

  • 9.1. Arteriovenous Malformation
  • 9.2. Brain Tumor
  • 9.3. Metastatic Brain Disease
  • 9.4. Trigeminal Neuralgia

10. Gamma Beam Stereotactic Radiotherapy System Market, by End User

  • 10.1. Academic And Research Institutes
  • 10.2. Ambulatory Surgical Centers
  • 10.3. Cancer Research Institutes
  • 10.4. Hospitals

11. Gamma Beam Stereotactic Radiotherapy System Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Gamma Beam Stereotactic Radiotherapy System Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Gamma Beam Stereotactic Radiotherapy System Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States Gamma Beam Stereotactic Radiotherapy System Market

15. China Gamma Beam Stereotactic Radiotherapy System Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. Accuray Incorporated
  • 16.6. Brainlab AG
  • 16.7. C-Rad AB
  • 16.8. Canon Medical Systems Corporation
  • 16.9. Elekta AB
  • 16.10. GE Healthcare
  • 16.11. Hitachi, Ltd.
  • 16.12. IBA Worldwide
  • 16.13. LinaTech LLC
  • 16.14. Mevion Medical Systems, Inc.
  • 16.15. Mitsubishi Electric Corporation
  • 16.16. Neusoft Medical Systems Co., Ltd.
  • 16.17. Philips Healthcare
  • 16.18. ProTom International, Inc.
  • 16.19. RaySearch Laboratories AB
  • 16.20. Shenzhen Anke High-tech Co., Ltd.
  • 16.21. Shinva Medical Instrument Co., Ltd.
  • 16.22. Sumitomo Heavy Industries, Ltd.
  • 16.23. TopGrade HealthCare Inc.
  • 16.24. Toshiba Corporation
  • 16.25. United Imaging Healthcare Co., Ltd.
  • 16.26. Varian Medical Systems, Inc.
  • 16.27. ViewRay, Inc.
  • 16.28. Wandong Medical Equipment Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY HARDWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY HARDWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY HARDWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COLLIMATOR SYSTEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COLLIMATOR SYSTEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COLLIMATOR SYSTEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COLLIMATOR SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY FIXED COLLIMATOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY FIXED COLLIMATOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY FIXED COLLIMATOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SECTOR COLLIMATOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SECTOR COLLIMATOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SECTOR COLLIMATOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY IMAGING SYSTEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY IMAGING SYSTEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY IMAGING SYSTEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY IMAGING SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY CT BASED IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY CT BASED IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY CT BASED IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY MRI BASED IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY MRI BASED IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY MRI BASED IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY PATIENT POSITIONING SYSTEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY PATIENT POSITIONING SYSTEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY PATIENT POSITIONING SYSTEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY DELIVERY CONTROL SYSTEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY DELIVERY CONTROL SYSTEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY DELIVERY CONTROL SYSTEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY TREATMENT PLANNING PLATFORM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY TREATMENT PLANNING PLATFORM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY TREATMENT PLANNING PLATFORM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY INSTALLATION & COMMISSIONING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY INSTALLATION & COMMISSIONING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY INSTALLATION & COMMISSIONING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY PREVENTIVE MAINTENANCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY PREVENTIVE MAINTENANCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY PREVENTIVE MAINTENANCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY TRAINING & SUPPORT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY TRAINING & SUPPORT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY TRAINING & SUPPORT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY ARTERIOVENOUS MALFORMATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY ARTERIOVENOUS MALFORMATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY ARTERIOVENOUS MALFORMATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY BRAIN TUMOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY BRAIN TUMOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY BRAIN TUMOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY METASTATIC BRAIN DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY METASTATIC BRAIN DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY METASTATIC BRAIN DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY TRIGEMINAL NEURALGIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY TRIGEMINAL NEURALGIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY TRIGEMINAL NEURALGIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COLLIMATOR SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY IMAGING SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COLLIMATOR SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY IMAGING SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COLLIMATOR SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY IMAGING SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COLLIMATOR SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY IMAGING SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COLLIMATOR SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY IMAGING SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COLLIMATOR SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY IMAGING SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COLLIMATOR SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY IMAGING SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COLLIMATOR SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY IMAGING SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COLLIMATOR SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY IMAGING SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. GCC GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GCC GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 164. GCC GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 165. GCC GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COLLIMATOR SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 166. GCC GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY IMAGING SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 167. GCC GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 168. GCC GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 169. GCC GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 170. GCC GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COLLIMATOR SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY IMAGING SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COLLIMATOR SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY IMAGING SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. G7 GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. G7 GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 191. G7 GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 192. G7 GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COLLIMATOR SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 193. G7 GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY IMAGING SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 194. G7 GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 195. G7 GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 196. G7 GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 197. G7 GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. NATO GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. NATO GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 200. NATO GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 201. NATO GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COLLIMATOR SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 202. NATO GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY IMAGING SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 203. NATO GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 204. NATO GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 205. NATO GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 206. NATO GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COLLIMATOR SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY IMAGING SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY HARDWARE, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY COLLIMATOR SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY IMAGING SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA GAMMA BEAM STEREOTACTIC RADIOTHERAPY SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)